November 22, 2011
The New York Academy of Sciences (NYAS) will be holding an event, Biomarkers and Brain Imaging of Presymptomatic Alzheimer's Disease: Exploring the Silent Years, on Tuesday, January 24, 2012 from 1:00 PM to 5:00 PM. The symposium is being organized by Robert Martone from the Covance Biomarker Center of Excellence, Robert B. Nelson, Ph.D., Lundbeck Research USA, Ken Jones, Ph.D., Biochemical Pharmacology Discussion Group, and Jennifer Henry, Ph.D., The New York Academy of Sciences.
As we move toward an increasingly elderly demographic, Alzheimer's disease (AD) is set to become the most devastating healthcare crisis facing society in the 21st century. With the advent of new clinical tools, there is an increasing appreciation that the events leading to AD may begin years and even decades prior to diagnosis. The availability of amyloid imaging agents provides one striking example: Fibrillar amyloid deposits, once considered "tombstone markers" occurring well after diagnosis of AD, are now known to occur a decade or more prior to diagnosis on average. The goal of this symposium is to explore an integrated view of the structural, functional, and biochemical events that may precede and predict both AD and amnestic mild cognitive impairment (aMCI). The available tools include imaging agents for amyloid deposits, FDG-PET, structural MRI, default network functional MRI, and a plethora of potential CSF and plasma biochemical markers. Developing and refining this integrated view of what these clinical tools are able to reveal is essential to gaining clues about key causal events leading to AD, to understanding how measurable functional deficits in the brain might be detected behaviorally, and to establishing and validating surrogate biomarkers predictive of AD onset.
Bradley T. Hyman, M.D., Ph.D., Massachussets General Hospital
Tentative presentation title: Relating pre-morbid changes in human brain with pathological events recapitulated in A-beta-depositing transgenic mice
Simon Lovestone, Ph.D., MRCPsych, MRC Centre for Neurodegeneration Research, London
Tentative presentation title: Plasma markers and CSF-based biomarkers for aMCI and AD: Relationship to pathogenesis, conversion, and progression rate
John C. Morris, M.D., Washington University School of Medicine
Tentative presentation title: New perspectives on 'silent' brain amyloidosis: Relationships to other markers of preclinical AD and risk for AD dementia
Reisa Sperling, M.D., Brigham and Women's Hospital and Harvard Medical School
Tentative presentation title: Molecular and functional imaging of preclinical alzheimer's disease: Defining cohorts for secondary prevention trials
Registration for NYAS members is free and for nonmembers $30. For more information, including speakers, sponsors, and travel & lodging, see the NYAS symposium page.Date & Time: Tuesday, January 24, 2012, 1:00 PM - 5:00 PM